TickerStat.comEloxx Pharmaceuticals annual cash and equivalents
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Cash & Equivalents Growth & History (ELOX)
Eloxx Pharmaceuticals's cash and equivalents was $4.8M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.8M | $4.7M | +4210.81% |
| 2024 | 2024-12-31 | $111,000 | −$1.0M | −90.21% |
| 2023 | 2023-12-31 | $1.1M | −$18.1M | −94.10% |
| 2022 | 2022-12-31 | $19.2M | −$23.1M | −54.56% |
| 2021 | 2021-12-31 | $42.3M | $17.6M | +71.35% |
| 2020 | 2020-12-31 | $24.7M | $2.2M | +9.67% |
| 2019 | 2019-12-31 | $22.5M | −$26.1M | −53.72% |
| 2018 | 2018-12-31 | $48.6M | $24.6M | +102.11% |
| 2017 · Dec 31 | 2017-12-31 | $24.0M | $21.8M | +987.21% |
| 2017 · Jun 30 | 2017-06-30 | $33,198 | −$777,610 | −95.91% |
| 2016 · Dec 31 | 2016-12-31 | $2.2M | $842,000 | +61.46% |
| 2016 · Jun 30 | 2016-06-30 | $810,808 | −$2.5M | −75.69% |
| 2015 · Dec 31 | 2015-12-31 | $1.4M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $3.3M | −$2.8M | −45.44% |
| 2014 | 2014-06-30 | $6.1M | $4.5M | +281.41% |
| 2013 | 2013-06-30 | $1.6M | −$399,031 | −19.94% |
| 2012 | 2012-06-30 | $2.0M | −$1.6M | −44.56% |
| 2011 | 2011-06-30 | $3.6M | −$4.4M | −55.02% |
| 2010 | 2010-06-30 | $8.0M | $7.6M | +2009.03% |
| 2009 | 2009-06-30 | $380,569 | — | — |
Eloxx Pharmaceuticals quarterly cash and equivalents
Q4.10
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $62.0M | — | — |
| Q1 2026 | 2026-03-31 | $6.4M | — | — |
| Q4 2025 | 2025-12-31 | $4.8M | $4.7M | +4210.81% |
| Q4 2024 | 2024-12-31 | $111,000 | −$1.0M | −90.21% |
| Q4 2023 | 2023-12-31 | $1.1M | −$18.1M | −94.10% |
| Q3 2023 | 2023-09-30 | $4.8M | −$19.8M | −80.55% |
| Q2 2023 | 2023-06-30 | $4.3M | −$25.7M | −85.59% |
| Q1 2023 | 2023-03-31 | $4.9M | −$34.9M | −87.67% |
| Q4 2022 | 2022-12-31 | $19.2M | −$23.1M | −54.56% |
| Q3 2022 | 2022-09-30 | $24.6M | −$27.9M | −53.17% |
| Q2 2022 | 2022-06-30 | $30.0M | −$26.7M | −47.04% |
| Q1 2022 | 2022-03-31 | $39.8M | $21.5M | +117.94% |
| Q4 2021 | 2021-12-31 | $42.3M | $17.6M | +71.35% |
| Q3 2021 | 2021-09-30 | $52.4M | $21.8M | +71.39% |
| Q2 2021 | 2021-06-30 | $56.7M | $26.4M | +86.95% |
| Q1 2021 | 2021-03-31 | $18.2M | −$7.6M | −29.48% |
| Q4 2020 | 2020-12-31 | $24.7M | $2.2M | +9.67% |
| Q3 2020 | 2020-09-30 | $30.6M | $8.4M | +38.08% |
| Q2 2020 | 2020-06-30 | $30.3M | −$19.0M | −38.48% |
| Q1 2020 | 2020-03-31 | $25.9M | −$18.7M | −41.95% |
| Q4 2019 | 2019-12-31 | $22.5M | −$26.1M | −53.72% |
| Q3 2019 | 2019-09-30 | $22.2M | −$33.2M | −59.96% |
| Q2 2019 | 2019-06-30 | $49.3M | −$14.1M | −22.21% |
| Q1 2019 | 2019-03-31 | $44.6M | $26.3M | +143.72% |
| Q4 2018 | 2018-12-31 | $48.6M | $24.6M | +102.11% |
| Q3 2018 | 2018-09-30 | $55.3M | $54.4M | +5676.96% |
| Q2 2018 | 2018-06-30 | $63.4M | $63.4M | +190911.51% |
| Q1 2018 · Mar 31 | 2018-03-31 | $18.3M | $18.0M | +7459.41% |
| Q4 2017 · Dec 31 | 2017-12-31 | $24.0M | $21.8M | +987.21% |
| Q1 2018 · Sep 30 | 2017-09-30 | $957,874 | $670,810 | +233.68% |
| Q4 2017 · Jun 30 | 2017-06-30 | $33,198 | −$777,610 | −95.91% |
| Q1 2017 · Mar 31 | 2017-03-31 | $241,950 | −$1.3M | −84.14% |
| Q4 2016 · Dec 31 | 2016-12-31 | $2.2M | $842,000 | +61.46% |
| Q1 2017 · Sep 30 | 2016-09-30 | $287,064 | −$3.1M | −91.44% |
| Q4 2016 · Jun 30 | 2016-06-30 | $810,808 | −$2.5M | −75.69% |
| Q1 2016 · Mar 31 | 2016-03-31 | $1.5M | $1.1M | +224.61% |
| Q4 2015 · Dec 31 | 2015-12-31 | $1.4M | −$737,452 | −34.99% |
| Q1 2016 · Sep 30 | 2015-09-30 | $3.4M | −$482,270 | −12.57% |
| Q4 2015 · Jun 30 | 2015-06-30 | $3.3M | −$2.8M | −45.44% |
| Q3 2015 | 2015-03-31 | $469,980 | −$5.7M | −92.42% |
| Q2 2015 | 2014-12-31 | $2.1M | −$4.0M | −65.58% |
| Q1 2015 | 2014-09-30 | $3.8M | $3.0M | +386.22% |
| Q4 2014 | 2014-06-30 | $6.1M | $4.5M | +281.41% |
| Q3 2014 | 2014-03-31 | $6.2M | $4.6M | +292.02% |
| Q2 2014 | 2013-12-31 | $6.1M | $5.5M | +856.36% |
| Q1 2014 | 2013-09-30 | $789,176 | −$522,880 | −39.85% |
| Q4 2013 | 2013-06-30 | $1.6M | −$399,031 | −19.94% |
| Q3 2013 | 2013-03-31 | $1.6M | −$1.6M | −50.70% |
| Q2 2013 | 2012-12-31 | $640,125 | −$912,773 | −58.78% |
| Q1 2013 | 2012-09-30 | $1.3M | −$1.5M | −53.83% |
| Q4 2012 | 2012-06-30 | $2.0M | −$1.6M | −44.56% |
| Q3 2012 | 2012-03-31 | $3.2M | — | — |
| Q2 2012 | 2011-12-31 | $1.6M | — | — |
| Q1 2012 | 2011-09-30 | $2.8M | — | — |
| Q4 2011 | 2011-06-30 | $3.6M | −$4.4M | −55.02% |
| Q4 2010 | 2010-06-30 | $8.0M | — | — |
Eloxx Pharmaceuticals cash and equivalents trends
Over the last five fiscal years, Eloxx Pharmaceuticals's cash and equivalents decreased from $24.7M to $4.8M, a change of −$19.9M. The latest reported quarter, Q2 2026, shows $62.0M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...